» Articles » PMID: 11735689

Aortic and Mitral Fenfluramine-phentermine Valvulopathy in 64 Patients Treated with Anorectic Agents

Overview
Specialty Pathology
Date 2001 Dec 12
PMID 11735689
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Context: Few published studies of the pathology of fenfluramine-phentermine (fen-phen) valvulopathy, described by Connolly and colleagues in 1997, have appeared.

Objectives: To define temporal changes in the morphology of the stuck-on plaques and to determine whether the plaques progress or regress after cessation of fen-phen.

Methods: The available clinical information and pathology material from 35 aortic valves (AVs) and 43 mitral valves (MVs) from 64 patients were reviewed.

Results: The valves fell into 3 groups: 17 AVs and 28 MVs had fen-phen lesions only, 2 AVs and 7 MVs had fen-phen changes associated with other valve diseases, and 16 AVs and 8 MVs had no fen-phen changes. Fenfluramine-phentermine-attributable dysfunction was regurgitation in all instances. Typical plaques showed proliferation of myofibroblastic cells with myxoid stroma. Small vascular channels and slight lymphocytic accumulations were often present. Deeper parts of some plaques had dense fibroelastic tissue underlying typical plaque.

Conclusions: Considerable individual variation in the time course of anorectic agent use and the severity of fen-phen valvulopathy was observed. Possible plaque regression could not be assessed from this study. The observations suggest that in some patients fen-phen-induced plaques may continue to have surface proliferation despite drug withdrawal.

Citing Articles

Serotonin transporter deficiency in mice results in an increased susceptibility to HTR2B-dependent pro-fibrotic mechanisms in the cardiac valves and left ventricular myocardium.

Castillero E, Camillo C, Levine D, DAngelo A, Kosuri Y, Grau J Cardiovasc Pathol. 2024; 74:107689.

PMID: 39245153 PMC: 11585425. DOI: 10.1016/j.carpath.2024.107689.


Decreased serotonin transporter activity in the mitral valve contributes to progression of degenerative mitral regurgitation.

Castillero E, Fitzpatrick E, Keeney S, DAngelo A, Pressly B, Simpson M Sci Transl Med. 2023; 15(677):eadc9606.

PMID: 36599005 PMC: 9896655. DOI: 10.1126/scitranslmed.adc9606.


Key Characteristics of Cardiovascular Toxicants.

Lind L, Araujo J, Barchowsky A, Belcher S, Berridge B, Chiamvimonvat N Environ Health Perspect. 2021; 129(9):95001.

PMID: 34558968 PMC: 8462506. DOI: 10.1289/EHP9321.


Drug-associated valvular heart diseases and serotonin-related pathways: a meta-analysis.

Fortier J, Pizzarotti B, Shaw R, Levy R, Ferrari G, Grau J Heart. 2019; 105(15):1140-1148.

PMID: 31129607 PMC: 7043398. DOI: 10.1136/heartjnl-2018-314403.


The Salford Lung Study: a pioneering comparative effectiveness approach to COPD and asthma in clinical trials.

Albertson T, Murin S, Sutter M, Chenoweth J Pragmat Obs Res. 2017; 8:175-181.

PMID: 29033625 PMC: 5614786. DOI: 10.2147/POR.S144157.